Metropolitan Life Insurance Co. NY lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,376 shares of the medical research company’s stock after selling 19 shares during the period. Metropolitan Life Insurance Co. NY owned 0.07% of Bio-Rad Laboratories worth $3,862,000 as of its most recent SEC filing.
A number of other institutional investors have also bought and sold shares of the company. FMR LLC acquired a new position in Bio-Rad Laboratories during the fourth quarter worth approximately $30,186,000. Bank of New York Mellon Corp boosted its stake in shares of Bio-Rad Laboratories by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 244,936 shares of the medical research company’s stock worth $48,826,000 after buying an additional 15,496 shares in the last quarter. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Bio-Rad Laboratories during the first quarter worth about $1,253,000. Great West Life Assurance Co. Can boosted its stake in shares of Bio-Rad Laboratories by 3.9% in the first quarter. Great West Life Assurance Co. Can now owns 12,380 shares of the medical research company’s stock worth $2,467,000 after buying an additional 469 shares in the last quarter. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Bio-Rad Laboratories by 23.8% in the first quarter. Parametric Portfolio Associates LLC now owns 90,855 shares of the medical research company’s stock worth $18,111,000 after buying an additional 17,492 shares in the last quarter. Institutional investors and hedge funds own 63.70% of the company’s stock.
Shares of Bio-Rad Laboratories, Inc. (NYSE BIO) traded down 6.18% on Friday, hitting $227.31. 608,428 shares of the stock traded hands. The firm has a market cap of $6.73 billion, a P/E ratio of 241.31 and a beta of 0.91. Bio-Rad Laboratories, Inc. has a 52 week low of $143.39 and a 52 week high of $239.91. The stock has a 50-day moving average price of $228.57 and a 200 day moving average price of $210.72.
Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.14. Bio-Rad Laboratories had a net margin of 1.35% and a return on equity of 3.23%. The business had revenue of $500.05 million for the quarter, compared to analysts’ expectations of $477.76 million. During the same period last year, the business earned $0.42 EPS. The company’s revenue was up 6.1% compared to the same quarter last year. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post $2.94 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/metropolitan-life-insurance-co-ny-reduces-stake-in-bio-rad-laboratories-inc-bio-updated-updated-updated/1180112.html.
Several equities research analysts recently issued reports on the company. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research note on Thursday. Zacks Investment Research downgraded shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Jefferies Group LLC restated a “buy” rating and set a $250.00 price objective on shares of Bio-Rad Laboratories in a research report on Thursday, April 27th. Deutsche Bank AG upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and lowered their price objective for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $228.80.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with our FREE daily email newsletter.